



Nanosonics to Showcase Innovative trophon2 at ACOG 2019 Annual Meeting

HLD solution proven to reduce risk of ultrasound probe cross-infection without harm to environment

NASHVILLE, Tenn., May 2, 2019 – [Nanosonics](#) (ASX: NAN), a leader in infection prevention solutions, announced it will highlight the proprietary [trophon[®]2](#) system, the latest innovation in ultrasound probe high level disinfection (HLD) at the American College of Obstetricians and Gynecologists ([ACOG](#)) Annual Meeting.

Nanosonics' trophon2 offers a complete reprocessing solution to optimize ultrasound probe decontamination while helping to ensure compliance with the latest guideline requirements without the use of hazardous chemicals.

"In the private office setting, it's important for me to be able to provide high-quality ultrasound capabilities to my patients," said Steven W. Tucker, M.D., FACOG, president and medical director of Advanced Menstrual Care Center in Townson, Md. "This, coupled with my commitment to quality and safety, necessitates that I use trophon2, as it is the only option there is for complete patient safety and full compliance."

The trophon* technology's high-frequency ultrasonic vibrations generate a sonically activated, supercharged hydrogen peroxide (H₂O₂) mist that inactivates an extended range of infectious pathogens that other HLD products do not, including Sexually Transmitted Infections (STIs), Clostridium difficile spores and drug resistant bacteria.# trophon is a pioneer globally in microbial efficacy, the first HLD system in the world proven to kill native, infectious, high-risk HPV¹.

"To deliver maximum patient safety, disinfection and infection control methods need to meet or exceed today's demanding guidelines and requirements," said Peter McGovern, M.D., medical director for University Reproductive Associates of New Jersey. "After investigating Nanosonics' trophon technology, we quickly realized it was the only option available that would keep our patients safe and give us peace of mind. There is no substitute for patient safety and security in modern medical care."

"We are excited to showcase our trophon2 for the first time to attendees of ACOG 2019, and this year's meeting focus on clinically relevant innovations that are practice-ready couldn't be more pertinent," said Ken Shaw, president of North America for Nanosonics. "Considered the new standard of care in Ob/Gyn, trophon is recognized as the leading automated HLD solution for transvaginal, transrectal and surface probes. It delivers a smarter option that provides [the broadest possible microbial efficacy](#) to dramatically reduce the risk of cross infection from ultrasound probes."

Nanosonics' trophon systems are installed in more than 4,000 hospitals and facilities in North America including all of the top 50 U.S. hospitals** and it's estimated that trophon technology is reducing the risk of cross-contamination for over 60,000 patients daily. The device is compatible for use with over 1,000 probes.

To learn more about Nanosonics' HLD solution, please visit their booth #2119 during ACOG 2019, May 3-6 in the Nashville Music City Center, Nashville, Tenn.



About Nanosonics

[Nanosonics](#) (ASX:NAN) is a leading medical technology company headquartered in Sydney, Australia, with its North American operations based in Indianapolis. Founded in 2001, the company is one of Australia's largest medical technology companies and a recognized leader in its sector of the global infection control market. More information may be found at www.nanosonics.com.us.

*trophon [trophon EPR & trophon2]

1. Ryndock E, Robison R, Meyers C. Susceptibility of HPV16 and 18 to high level disinfectants indicated for semi-critical ultrasound probes. J Med Virol. 2016;88(6):1076-80.
Nanosonics internal test data

**US News and World Report.

Media Contact:

Amy Cook

amy@amcpublicrelations.com

<https://www.nanosonics.us/news/media-kit/>